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Summary Visceral leishmaniasis (VL) is a relatively rare occurrence in rheumatoid arthritis
(RA) patients treated with tumor necrosis factor-a (TNF-a) antagonists, corticosteroids and
methotrexate, or methotrexate alone. A review of the literature revealed that only one case of
VL in an RA patient treated with methotrexate has been previously published. We describe an
additional case, that of a 65-year-old female with RA being treated with methotrexate, who
presented with fever, abdominal discomfort, splenomegaly and pancytopenia. A diagnosis of VL
was ultimately established, after a splenectomy was performed. Because RA is characterized by
immune cell dysfunction and dysregulation, which potentially predisposes patients to infection, it
is unclear whether this serious opportunistic infection can be solely attributable to the metho-
trexate, an immunosuppressive medication that also increases the risk of infection.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Rheumatoid arthritis (RA) is a chronic multisystem disease of
unknown cause.1 It is characterized by immune cell dysfunc-
tion and dysregulation, which potentially predisposes
patients to infection. As the long-term use of immunosup-
pressive medication for RA, such as methotrexate, also
increases this particular risk, it is unclear whether this
increased infectious morbidity and mortality is solely attri-* Corresponding author. Department of Pathology, Hippokration
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doi:10.1016/j.ijid.2008.09.012butable to RA per se or represents sequelae of the immuno-
suppressive therapy, or a combination thereof. In addition, it
is often difficult to differentiate between reactivation of a
latent infection induced by immunosuppressive drugs and a
recent infection in an immunocompromised patient.
Case report
Herein, we report the case of a 65-year-old Caucasian female,
living in a rural area of central Greece,who had been suffering
from RA for the past eight years and was being treated with
methotrexate. She was admitted to our hospital complaining
of fever, night sweats, abdominal discomfort for two weeks,
and 10 kg weight loss over three months. On physical exam-
ination, her spleen was palpable approximately 20 cm belowPublished by Elsevier Ltd. All rights reserved.
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denopathy nor skin rashes were detected. She denied any
history of travel outside Greece. Laboratory findings were
as follows: erythrocyte sedimentation rate (ESR) 98 mm/hour;
white blood cell (WBC) count 2.9  109/l; platelets 114  109/
l; hematocrit (Ht) 29%; lactate dehydrogenase (LDH) 560 IU/L;
hypoalbuminemia 2.8 g/dl; and polyclonal hypergammaglobu-
linemia (chiefly involving IgG). The Mantoux test, Widal—
Wright reaction and serology for HIV, hepatitis B and C viruses
(HBV, HCV), Epstein—Barr virus (EBV), cytomegalovirus (CMV)
and toxoplasma were all negative.
Because of the splenomegaly and pancytopenia, a
splenectomy was recommended and finally performed.
The excised spleen weighted 1120 g and measured
21  15  5.5 cm.Histological examination displayeda hyper-
plastic red pulp containing an increased number of macro-
phages both in the cords and within the vascular sinuses.
Numerous reactive plasma cells were also noted (Figure 1).
A large proportion of the cortical macrophages were stuffed
with ingested parasites morphologically consistent with Leish-
mania organisms (Figure 2). The white pulp showed follicularFigure 1 Spleen section showing diffuse infiltration by histio-
cytes and plasma cells (hematoxylin and eosin stain (HE)  100).
Figure 2 Higher magnification image displaying numerous
plasma cells andmacrophages stuffed with abundant Leishmania
donovani bodies (hematoxylin and eosin stain (HE)  400).hyperplasia and occasional atrophy. Occasional arterioles
showed perivascular fibrosis with an ‘onion skin’ effect. On
the basis of pathological features alone, a diagnosis of visceral
leishmaniasis (VL) was considered. Subsequently, a bone mar-
rowbiopsy revealed abundant Leishmania parasites, and indir-
ect immunofluorescence antibody testing (ELISA) was strongly
positive for Leishmania. The patient was treated with liposo-
mal amphotericin-B for a total dose of 21 mg/kg (3 mg/kg per
day on days 1—5, day 14 and day 21). Four years later, she is
clinically stablewith no further clinical or biological symptoms
of leishmaniasis detected.
Discussion
Leishmaniasis is caused by a group of obligate intra-macro-
phage protozoan parasites transmitted to humans by approxi-
mately 30 different species of phlebotomine sandflies.2,3
There are three general forms of leishmaniasis [cutaneous
leishmaniasis (CL); muco-cutaneous leishmaniasis; and visc-
eral leishmaniasis (VL) or kala-azar] and three rare clinical
variants of CL [diffuse cutaneous leishmaniasis; leishmaniasis
recidivans (recurrent leishmaniasis); and post-kala-azar der-
mal leishmaniasis].3,4 VL results from infection with Leish-
mania donovani or Leishmania infantum (Leishmania
donovani complex) and is endemic in some parts of South
America, Africa, China, India and the Mediterranean basin.3,5
Apart from the aforementioned clinical syndromes, HIV-
associated leishmaniasis has been recognized in increasing
numbers over the past two decades.5 In addition, malnutri-
tion or impaired immunocompetence (other than that
related to HIV) associated with young age, neoplastic dis-
eases, transplantation and immunosuppressive therapy
increase the risk of VL manifestation after Leishmania infec-
tion.3,5—8 The development of VL in cancer patients has been
more frequently reported with hematologic malignancies
rather than solid tumors.9 VL in organ transplant recipients
has been most commonly associated with renal transplanta-
tion.10 VL was formerly a disease of childhood. Clinical VL in
older age groups might be attributable to the increased
travel of otherwise immunocompromised elderly subjects
to endemic regions, or to the increased proportion of Leish-
mania and HIV co-infected subjects.7,8
The pathogenesis of the disease is a mixture of the direct
effects of the organism on infected cells and the host
response to the infectious process.3 Interestingly, disease
expression largely depends on the species of the infecting
parasite, whereas the course of infection is based on the
host-specific cell-mediated immune response.4 In experi-
mental leishmaniasis, two distinct subsets of T-helper cells
are crucial in inducing susceptibility or resistance to infec-
tion. T-helper type 1 (Th1) cells produce IL-2, interferon-g,
tumor necrosis factor (TNF)-a and TNF-b, and enhance cell-
mediated immune responses by activating macrophages to
phagocytize and kill intracellular amastigotes. In addition,
IL-12 exerts its effect by inducing naive T cells to differenti-
ate into Th1 cells and by inducing both T cells and natural
killer cells to produce interferon-g. Th2 cells, which secrete
IL-4, IL-5 and IL-10, inhibit some cell-mediated immune
responses. Of importance, IL-10 has pleiotropic, primarily
deactivating effects on target cells, including antagonizing
dendritic cell functions and rendering macrophages unre-
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to control Leishmania donovani infection is associated not
only with an inadequate T-cell response (due to a Th1 defect
or Th2 dominance per se) to leishmanial antigens, but also
with concomitant production of IL-10, which might be trig-
gered as a potential homeostatic mechanism in order to limit
immune-mediated pathology.11,12
Experimental evidence, based on the mouse model,
strongly supports a potential role for IL-10, along with TNF,
as amediator of splenic pathology in VL. Although the spleen is
an initial site for the generation of cell-mediated immune
responses, it ultimately becomes a site of parasite persistence
with the associated immunopathology, encompassing spleno-
megaly and a breakdown in tissue architecture. In particular,
the pathology is mediated by the direct loss of specific cell
populations (follicular dendritic cell networks, marginal zone
macrophages, gp38+ stromal cells) and an array of changes to
the local tissue microenvironment that ultimately result in
fatality due to the immunocompromized status of the host.13
Of note, in VL, the white pulp becomes disorganized and
reduced in size (follicular atrophy), whereas the red pulp
becomes hyperplastic with heavily infected macrophages
demonstrated in multiple and unusual locations.
By contrast, reactive follicular hyperplasia is almost
always observed in untreated RA and Felty’s syndrome (a
complication of RA).14 Hyperplastic germinal centers, along
with an increase in the red pulp (expanded red pulp sinuses
and cords with a prominent macrophage population), con-
stitute the structural basis for the observed splenomegaly in
Felty’s syndrome.15 With regard to splenomegaly in uncom-
plicated RA, this represents a common, extra-articular fea-
ture of the disease. It is observed, upon manual palpation,
isotope scanning or abdominal ultrasonography, in 5—10% up
to 58% of patients with RA, while rendering them at risk of
experiencing spontaneous splenic rupture.15,16 Of interest,
an enlarged spleen in such cases might be attributed to a
mechanism similar to that in Felty’s syndrome, in which there
is an excessive margination of granulocytes caused by anti-
bodies to these cells, complement activation or binding of
immune complexes, suggesting that these patients might be
in an early stage of Felty’s syndrome.1,15,16
VL is a relatively rare event inRApatients treatedwithTNF-
a antagonists; only four reports have been described (two
treated with adalimumab, one treated with infliximab, one
treated with etanercept). TNF-a blockade results in deactiva-
tion of T and B lymphocytes, and macrophages necessary for
ingestion and killing of Leishmania pathogens.17—21 VL is also
rare in RA patients treated with corticosteroids/methotrex-
ate; only two cases have been reported.7,22 Glucocorticoids
affect the effector, suppressor and cytotoxic T-cell functions
through the blockade of cytokine expression, whereas metho-
trexate appears to decrease antigen-stimulated T-cell prolif-
eration, neutrophil chemotaxis and superoxide generation, as
well as T-cell release of TNF-a and interferon-g, in patients
with RA.6,17 Finally, to our knowledge, there are only two case
reports ofVL inRApatients treatedwithmethotrexate (includ-
ing the one described herein).7
With the increasing use of anti-TNFa therapy, the risk of
an increasing incidence of VL in leishmania endemic coun-
tries, such as those in the Mediterranean, is to be expected
and anticipated. However, because of the low incidence of
Mediterranean VL, it seems difficult to propose a systematicscreening for leishmaniasis in all patients treated with immu-
nobiologicals. Another point of clinical importance concerns
those patients returning from an endemic area with clinical
signs and symptoms characteristic of VL. As untreated VL is
fatal, clinicians should consider the diagnosis more rapidly in
order to ensure that pertinent laboratory evaluation is
employed and appropriate treatment is administered.
The clinical picture of our VL case was typically charac-
terized by fever, weight loss, splenomegaly and pancytope-
nia. The diagnosis relied on the splenic pathology, detection
of parasites in the bone marrow biopsy and indirect immuno-
fluorescence antibody testing. Although splenectomy was
recommended to relieve abdominal discomfort, ameliorate
hypersplenism, and pre-empt a splenic rupture and subse-
quent life-threatening hemorrhage, it was retrospectively
unnecessary.
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